These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 11600357

  • 1. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW, Cryptococcal Disease Active Surveillance Group.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
    [Abstract] [Full Text] [Related]

  • 2. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 3. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI, Claro R, Castro C, Serrano C, Colom MF, Martín-Mazuelos E.
    Chemotherapy; 2007 Feb; 53(4):300-5. PubMed ID: 17496416
    [Abstract] [Full Text] [Related]

  • 4. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
    Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ.
    J Clin Microbiol; 2005 May; 43(5):2163-7. PubMed ID: 15872236
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA.
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [Abstract] [Full Text] [Related]

  • 6. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 7. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 8. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 9. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [Abstract] [Full Text] [Related]

  • 10. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [Abstract] [Full Text] [Related]

  • 11. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH.
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [Abstract] [Full Text] [Related]

  • 12. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM.
    Rev Iberoam Micol; 2009 Sep 30; 26(3):194-7. PubMed ID: 19635445
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN.
    Antimicrob Agents Chemother; 2001 Oct 30; 45(10):2862-4. PubMed ID: 11557481
    [Abstract] [Full Text] [Related]

  • 14. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC, Kamiya S.
    Mycoses; 2007 Jan 30; 50(1):25-30. PubMed ID: 17302744
    [Abstract] [Full Text] [Related]

  • 15. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.
    Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U.
    J Antimicrob Chemother; 2003 Oct 30; 52(4):683-6. PubMed ID: 12951350
    [Abstract] [Full Text] [Related]

  • 16. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep 30; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 17. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R.
    J Antimicrob Chemother; 2007 Aug 30; 60(2):312-6. PubMed ID: 17553813
    [Abstract] [Full Text] [Related]

  • 18. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2005 Aug 30; 43(8):3807-10. PubMed ID: 16081915
    [Abstract] [Full Text] [Related]

  • 19. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
    Fujita S.
    Rinsho Byori; 1996 Apr 30; 44(4):373-8. PubMed ID: 8847821
    [Abstract] [Full Text] [Related]

  • 20. Antifungal susceptibilities of Cryptococcus neoformans.
    Archibald LK, Tuohy MJ, Wilson DA, Nwanyanwu O, Kazembe PN, Tansuphasawadikul S, Eampokalap B, Chaovavanich A, Reller LB, Jarvis WR, Hall GS, Procop GW.
    Emerg Infect Dis; 2004 Jan 30; 10(1):143-5. PubMed ID: 15078612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.